MMP3 immunoreactivity was present in 53 cases (98%) of BPH and 14 cases (70%) of pAdCs, while 35 (54%) cases of BPH and 10 (50%) cases of pAdCs were immunoreactive for MMP9. This evidence concerns the gene MMP3 and benign prostatic hyperplasia.